Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Filana Therapeutics Inc (FLNA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.45-21.15%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for FLNA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Net cash used in operations stays below $17 million in H1 2026 | Filana aims to limit cash use to $17 million in H1 2026. | Broken | Net cash used in operations exceeds $17 million in H1 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Net cash used in operations was $12.7 million during first-half of 2026 and below previous guidance.” “Net cash used in operations for second-half 2026 is expected to be in a range from $11 to $15 million, plus the $31.25 million litigation settlement funding described above.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-development story rather than an established earnings compounder. The long-term thesis is marked intact, but confidence is low and the evidence base is limited.
The available valuation signal describes FLNA as cheap versus peers, while model confidence is low. The priced-in evidence points to a turbulent sector regime, not a broader combination of expensive valuation, weak fundamentals, and sector turbulence.
Near term, management has continued scientific publications and community engagement around the TSC-related epilepsy program. Cash fell from $95.5 million at 2025-Q4 to $82.7 million at 2026-Q2, and management projects $36 million to $40 million in unrestricted cash at year-end 2026. The latest recorded earnings event was a beat, but a new litigation filing and a recent listing-rule notice add risk, and the next print is flagged for monitoring.
Over the multi-year view, the thesis hinges on advancing the epilepsy program while managing cash and liquidity. Near term, a guidance cut would be a meaningful negative, while continued strength from healthcare bellwethers could support sector momentum. A weakening jobs trend could add recession concerns, though the evidence does not establish how these factors would affect FLNA specifically.
For the next 1 to 3 years, FLNA remains a low-confidence, high-risk clinical-development thesis with continued program activity but meaningful liquidity and legal concerns. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS loss narrows toward -$0.25 next quarter | A supporting condition in Filana Therapeutics Inc's published investment case. The stated target is >=-0.25 USD_PER_SHARE. | Under Pressure | EPS loss worsens below -$0.25 next quarter | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage $31.25 million estimated loss from securities litigation | It plans to handle a $31.25 million loss from securities litigation. | Intact | Loss contingency rises above $31.25 million or unresolved by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.19 → $-1.19 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.19 | Unavailable | 1 / 0 |
| 2026-07-25 | $-1.19 | Unavailable | 1 / 0 |
| 2026-07-26 | $-1.19 | Unavailable | 1 / 0 |
| 2026-07-27 | $-1.19 | Unavailable | 1 / 0 |
| 2026-07-28 | $-1.19 | Unavailable | 1 / 0 |
| 2026-07-29 | $-1.19 | Unavailable | 1 / 0 |
| 2026-07-30 | $-1.19 | $0 | 1 / 1 |
| 2026-07-31 | $-1.19 | $0 | 1 / 1 |
| 2026-08-01 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-02 | $-1.19 | $0 | 1 / 1 |
| 2026-08-03 | $-1.19 | $0 | 1 / 1 |
| 2026-08-04 | $-1.19 | $0 | 1 / 1 |
| 2026-08-05 | $-1.19 | $0 | 1 / 1 |
| 2026-08-06 | $-1.19 | $0 | 1 / 1 |
| 2026-08-07 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-08 | $-1.19 | $0 | 1 / 1 |
| 2026-08-09 | $-1.19 | $0 | 1 / 1 |
| 2026-08-10 | $-1.19 | $0 | 1 / 1 |
| 2026-08-11 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-12 | $-1.19 | $0 | 1 / 1 |
| 2026-08-13 | $-1.19 | $0 | 1 / 1 |
| 2026-08-14 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-15 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-16 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-17 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-18 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-19 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-20 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-21 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-22 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-23 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-24 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-25 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-26 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-27 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-28 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-29 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-30 | $-1.19 | Unavailable | 1 / 0 |
| 2026-08-31 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-01 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-02 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-03 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-04 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-05 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-06 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-07 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-08 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-09 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-10 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-11 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-12 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-13 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-14 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-15 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-16 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-17 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-18 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-19 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-20 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-21 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-22 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-23 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-24 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-25 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-26 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-27 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-28 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-29 | $-1.19 | Unavailable | 1 / 0 |
| 2026-09-30 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-01 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-02 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-03 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-04 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-05 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-06 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-07 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-08 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-09 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-10 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-11 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-12 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-13 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-14 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-15 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-16 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-17 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-18 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-19 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-20 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-21 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-22 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-23 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-24 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-25 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-26 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-27 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-28 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-29 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-30 | $-1.19 | Unavailable | 1 / 0 |
| 2026-10-31 | $-1.19 | Unavailable | 1 / 0 |
| 2026-11-01 | $-1.19 | Unavailable | 1 / 0 |
| 2026-11-02 | $-1.19 | Unavailable | 1 / 0 |
| 2026-11-03 | $-1.19 | Unavailable | 1 / 0 |
| 2026-11-04 | $-1.19 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.